

# WHO Expert Committee on Specifications for Pharmaceutical Preparations

---

Fiftieth report



World Health  
Organization

The World Health Organization (WHO) was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

An annual subscription to this series, comprising about four to six such reports, costs CHF 150.00/US\$ 180.00 (CHF 105.00/US\$ 126.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int); order on line: <http://www.who.int/bookorders>).

W H O T e c h n i c a l R e p o r t S e r i e s  
9 9 6

# WHO Expert Committee on Specifications for Pharmaceutical Preparations

---

Fiftieth report

*This report contains the views of an international group of experts, and  
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health  
Organization**

WHO Library Cataloguing-in-Publication Data

Fiftieth report of the WHO Expert Committee on specifications for pharmaceutical preparations.

(WHO technical report series ; no. 996)

1.Pharmaceutical Preparations - standards. 2.Technology, Pharmaceutical - standards.

3.Drug Industry - legislation. 4.Quality Control.

I.World Health Organization. II.Series.

ISBN 978 92 4 120996 0

(NLM classification: QV 771)

ISBN 978 92 4 069548 1 (PDF)

ISSN 0512-3054

**© World Health Organization 2016**

All rights reserved. Publications of the World Health Organization are available on the WHO website ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website ([www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

**Printed in Italy**

# Contents

<b>WHO Expert Committee on Specifications for Pharmaceutical Preparations</b>	vi
<b>Declarations of interest</b>	xii
<b>1. Introduction</b>	1
<b>2. General policy</b>	3
2.1 Cross-cutting pharmaceutical quality assurance issues	3
2.2 International collaboration	4
<b>3. Quality control – specifications and tests</b>	7
3.1 <i>The International Pharmacopoeia</i>	7
3.1.1 Updates	7
3.1.2 Workplan 2015–2016	7
3.2 Specifications for medicines, including children's medicines and radiopharmaceuticals	10
3.2.1 Maternal, newborn, child and adolescent health medicines	10
3.2.2 Antimalarial medicines	11
3.2.3 Antituberculosis medicines	12
3.2.4 Medicines for tropical diseases	12
3.2.5 Medicines for chronic diseases and for mental health	12
3.2.6 Other anti-infective medicines	13
3.2.7 Other medicines	13
3.2.8 Radiopharmaceuticals	14
3.3 General policy	15
<b>4. Quality control – international reference materials (International Chemical Reference Substances and Infrared Reference Spectra)</b>	19
4.1 Update on International Chemical Reference Substances (ICRS), including report of the ICRS Board	19
4.2 General policy	20
4.2.1 Chapter on reference substances and reference spectra	20
<b>5. Quality control – national laboratories</b>	21
5.1 External quality assurance assessment scheme	21
5.2 Guidance on testing of “suspect” substandard/spurious/falsely-labelled/falsified/counterfeit medicines	21
<b>6. Prequalification of quality control laboratories</b>	22
6.1 Update on the prequalification of quality control laboratories	22
6.2 Update on WHO quality monitoring projects	22
<b>7. Quality assurance – collaboration initiatives</b>	23
7.1 International meetings of world pharmacopoeias	23
7.2 Good pharmacopoeial practices	23
7.3 FIP–WHO technical guidelines: points to consider in the provision by health-care professionals of children-specific preparations that are not available as authorized products	24

<b>8. Quality assurance – good manufacturing practices</b>	<b>26</b>
8.1 Update of WHO good manufacturing practices for biologicals	26
8.2 Update of questions and answers for WHO good manufacturing practices for active pharmaceutical ingredients	26
8.3 Update of WHO good manufacturing practices: validation	27
8.4 Update of model inspection report	27
8.5 Update and recommendations from the inspectors' meeting	28
8.5.1 Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms	28
8.5.2 Risk classification of inspection observations	28
8.6 Guidance on good data and record management practices	29
<b>9. Quality assurance – distribution and trade of pharmaceuticals</b>	<b>30</b>
9.1 Good trade and distribution practices for starting materials	30
9.2 WHO Certification scheme on the quality of pharmaceutical products moving in international commerce – questions and answers	30
9.3 Guidance on medicines quality surveys	31
9.4 Update on the monitoring and surveillance project	32
<b>10. Prequalification of priority essential medicines and active pharmaceutical ingredients</b>	<b>33</b>
10.1 Update on the Prequalification Team managed by WHO	33
10.2 Collaborative procedure between the World Health Organization (WHO) Prequalification Team and national regulatory authorities in the assessment and accelerated national registration of WHO-prequalified pharmaceutical products and vaccines	34
<b>11. Regulatory guidance</b>	<b>35</b>
11.1 Guidance for organizations performing in vivo bioequivalence studies	35
11.2 WHO general guidance on variations to multisource pharmaceutical products	35
11.3 Update of biowaiver principles for assessment of interchangeable multisource (generic) products	36
11.4 Update of biowaiver list based on the WHO Model List of Essential Medicines	37
11.5 Update of international comparator products list for equivalence assessment of interchangeable multisource (generic) products	37
11.6 Good regulatory practices	38
<b>12. Nomenclature, terminology and databases</b>	<b>40</b>
<b>13. Summary and recommendations</b>	<b>42</b>
<b>Acknowledgements</b>	<b>48</b>
<b>Annex 1</b>	
Good pharmacopoeial practices	67
<b>Annex 2</b>	
FIP–WHO technical guidelines: Points to consider in the provision by health-care professionals of children-specific preparations that are not available as authorized products	87

<b>Annex 3</b>	
WHO good manufacturing practices for biological products	111
<b>Annex 4</b>	
Guidance on good manufacturing practices: inspection report	149
<b>Annex 5</b>	
Guidance on good data and record management practices	165
<b>Annex 6</b>	
Good trade and distribution practices for pharmaceutical starting materials	211
<b>Annex 7</b>	
Guidelines on the conduct of surveys of the quality of medicines	227
<b>Annex 8</b>	
Collaborative procedure between the World Health Organization (WHO) Prequalification Team and national regulatory authorities in the assessment and accelerated national registration of WHO-prequalified pharmaceutical products and vaccines	263
<b>Annex 9</b>	
Guidance for organizations performing in vivo bioequivalence studies	305
<b>Annex 10</b>	
WHO general guidance on variations to multisource pharmaceutical products	347

# WHO Expert Committee on Specifications for Pharmaceutical Preparations

Geneva, 12–16 October 2015

## Members<sup>1</sup>

Professor Saleh A. Bawazir, Consultant, College of Pharmacy, King Saud Unit, Riyadh, Saudi Arabia (*Rapporteur*)

Professor Theo G. Dekker, Professor Emeritus, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa

Professor Jos Hoogmartens, Leuven, Belgium (*Co-chairperson*)

Professor Jin Shaohong, Chief Expert for Pharmaceutical Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China

Professor Henning G. Kristensen, Vedbaek, Denmark

Ms Gugu N. Mahlangu, Director-General, Medicines Control Authority of Zimbabwe, Harare, Zimbabwe (*Chairperson*)

Dr Justina A. Molzon, Bethesda, MD, USA

Mrs Lynda Paleshnuik, Arnprior, Ontario, Canada

Dr Jitka Sabartova, Prague, Czech Republic (*Rapporteur*)

## Temporary advisers<sup>2</sup>

Professor Erwin Adams, Laboratorium voor Farmaceutische Analyse, Leuven, Belgium

Dr Marius Brits, Director, WHO Collaborating Centre for the Quality Assurance of Medicines, North-West University, Potchefstroom, South Africa

Dr Mônica da Luz Carvalho Soares, Expert Health Regulation, Brazilian Health Surveillance Agency (ANVISA), Brasilia, Brazil

2016

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/repor>